Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: February 26, 2026
Reporting Period: Quarterly and fiscal year ended December 31, 2025.
This filing serves as a notification that the Company issued a press release and an earnings presentation regarding its financial results for the period ended December 31, 2025. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) and is not included in the body of this 8-K text.
Key Financial Metrics
The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being disclosed in the attached press release (Exhibit 99.1) and earnings presentation (Exhibit 99.2).
Material Changes
The filing does not contain specific data regarding material changes versus prior periods. Investors must refer to the attached exhibits for comparative financial analysis.
Guidance, Outlook, and Risks
Management Commentary: The Company released an earnings presentation (Exhibit 99.2) which typically contains management commentary, outlook, and guidance, though the specific content is not detailed in this filing summary.
Risks and Contingencies: No specific risks or contingencies are described in the text of this 8-K. Standard risk disclosures are expected to be found in the attached exhibits or the Company's most recent 10-K/10-Q filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for the quarter and year ended December 31, 2025.
- Examine Exhibit 99.2 (Earnings Presentation) for forward-looking guidance, product pipeline updates, and management's discussion of financial condition.
- Verify the Company's liquidity position and debt obligations as detailed in the attached exhibits, as this 8-K does not list these values.
- Confirm the trading symbol (COLL) and exchange (NASDAQ Global Select Market) for accurate market data correlation.